Exact Sciences Corp (EXAS)

Add to Watchlists
Create an Alert
Quickflows
93.98 -2.22  -2.31% NASDAQ Oct 22, 16:00 93.00 -0.98  -1.04% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All EXAS News

News

View All Events

Events

Date Type Description
11/02/2021 Earnings Results Q3 2021 Earnings Results
11/02/2021 17:00 EST Earnings Calls Q3 2021 Earnings Call
07/28/2021 Earnings Results Q2 2021 Earnings Results
07/28/2021 17:00 EST Earnings Calls Q2 2021 Earnings Call
06/30/2021 11:00 EST AGM 2021 Annual General Meeting
05/04/2021 Earnings Results Q1 2021 Earnings Results
05/04/2021 17:00 EST Earnings Calls Q1 2021 Earnings Call
02/16/2021 Earnings Results Q4 2020 Earnings Results
02/16/2021 17:00 EST Earnings Calls Q4 2020 Earnings Call
10/29/2020 17:00 EST Earnings Calls Q3 2020 Earnings Call
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 1.712B
Total Expenses (TTM) 2.593B
Net Income (TTM) -864.77M

Balance Sheet View Statement

Total Assets (Quarterly) 6.724B
Total Liabilities (Quarterly) 3.165B
Shareholders Equity (Quarterly) 3.559B

Cash Flow Statement View Statement

Cash from Operations (TTM) 156.29M
Cash from Investing (TTM) -1.401B
Cash from Financing (TTM) 904.60M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
  • URL: https://www.exactsciences.com
  • Investor Relations URL: https://investor.exactsciences.com/investor-relations/default.aspx
  • HQ State/Province: Wisconsin
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Nov. 02, 2021
  • Last Earnings Release: Jul. 28, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 93.98
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
ARKG ARK Genomic Revolution ETF 5.22%
SPYGX Spyglass Growth Institutional 4.50%
DFRIX Delaware Smid Cap Growth R 3.87%
BBH VanEck Biotech ETF 3.25%
EARK.NO Emerge ARK Global Disruptive Innovt ETF 3.25%
FBT First Trust NYSE Arca Biotech ETF 3.24%
ARKK ARK Innovation ETF 3.03%
ETCGX Eventide Gilead C 2.47%
GOFFX Invesco Global Opportunities R5 2.30%
TRUZX T. Rowe Price New Horizons Z 2.02%
APHMX Artisan Mid Cap Institutional 1.82%
HQH Tekla Healthcare Investors 0.96%

Comparables

Edit
NVTA Invitae Corp
ILMN Illumina Inc
NTRA Natera Inc
SENS Senseonics Holdings Inc
PGNY Progyny Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.